Hua Medicine (Shanghai) Ltd.
HKEX:2552.HK
1.19 (HKD) • At close September 19, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Hua Medicine (Shanghai) Ltd. |
Symbool | 2552.HK |
Munteenheid | HKD |
Prijs | 1.19 |
Beurswaarde | 1,166,822,722 |
Dividendpercentage | 0% |
52-weken bereik | 1.03 - 2.65 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Dr. Li Chen Ph.D. |
Website | https://www.huamedicine.com |
An error occurred while fetching data.
Over Hua Medicine (Shanghai) Ltd.
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)